Peroxisome proliferator-activated receptor-gamma (PPARγ) agonists such as rosiglitazone and pioglitazone have shown promising therapeutic potential against Alzheimer's disease (AD) in preclinical studies1, 2, 3, 4, 5. The gene discussed is PPARG; the disease is Alzheimer disease.